Currently, there are 205.77M common shares owned by the public and among those 198.50M shares have been available to trade.
Insiders at the company have transacted a total of 20 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 16 of these insider trades were purchases, accounting for 202,807 shares. Insider sales of the common stock occurred on 4 occasions, with total insider shares sold totaling 48,866 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 5.89, down -0.18%. The company’s stock has a 5-day price change of -1.58% and 3.50% over the past three months. BCRX shares are trading -6.18% year to date (YTD), with the 12-month market performance down to -36.35% lower. It has a 12-month low price of $4.82 and touched a high of $9.06 over the same period. BCRX has an average intraday trading volume of 4.02 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.46%, -3.92%, and -14.84% respectively.
Institutional ownership of Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares accounts for 84.63% of the company’s 205.77M shares outstanding.
It has a market capitalization of $1.16B and a beta (3y monthly) value of 1.92. The earnings-per-share (ttm) stands at -$1.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.18% over the week and 6.29% over the month.
Analysts forecast that Biocryst Pharmaceuticals Inc. (BCRX) will achieve an EPS of -$0.21 for the current quarter, -$0.17 for the next quarter and -$0.35 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.34 while analysts give the company a high EPS estimate of -$0.14. Comparatively, EPS for the current quarter was -$0.28 a year ago. Earnings per share for the fiscal year are expected to increase by 48.00%, and 50.39% over the next financial year. EPS should grow at an annualized rate of 44.80% over the next five years, compared to -3.73% over the past 5-year period.
Looking at the support for the BCRX, a number of firms have released research notes about the stock. JP Morgan stated their Overweight rating for the stock in a research note on November 20, 2023, with the firm’s price target at $10. RBC Capital Mkts coverage for the Biocryst Pharmaceuticals Inc. (BCRX) stock in a research note released on September 18, 2023 offered a Outperform rating with a price target of $10. Jefferies was of a view on August 04, 2023 that the stock is Buy, while BofA Securities gave the stock Buy rating on July 13, 2023, issuing a price target of $10. Needham on their part issued Buy rating on February 22, 2023.
